Evidence review: Open Peptide Project (verified against primary PubMed, ClinicalTrials.gov & FDA records) · Last checked 2026-10-27. ← Back to Evidence Library · Trial & Regulatory Tracker →

CT-388 (enicepatide, RO7795068): what the evidence says

Name: CT-388 (enicepatide, RO7795068)
Published: 2026-10-27

At a glance

What it is: a once-weekly injected peptide that activates both the GLP-1 and GIP receptors, designed to be "biased" toward cAMP signaling with little receptor internalization. Developed by Carmot Therapeutics, now owned by Roche. ^R1

What the evidence says: Human in a 4-week phase 1 trial in people with overweight or obesity, weight fell 4.7% to 8.0% across doses vs 0.5% with placebo. ^R1 A 469-person phase 2 trial finished in Dec 2025 ^R2; we found no peer-reviewed results. UNVERIFIED any phase 2 weight-loss figure.

Biggest risks: the usual incretin side effects (nausea, vomiting, diarrhea); long-term safety unknown. ^R1

Rating


Human Human evidence	Limited: one 4-week phase 1 ^R1
Animal Animal / lab evidence	Mice and monkeys ^R1
Regulatory	Investigational · not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page ^{R3, R4, R5} · not named on WADA's 2026 list; as a drug not approved anywhere for human use it falls under S0 (non-approved substances) ^R6
Established human dose	No

Evidence verdict: Weight loss: Limited (one published 4-week phase 1; phase 2 completed, unpublished) · Type 2 diabetes: Unknown

This page reports what studies used. It is not dosing advice.

Legend: HUMAN data · ANIMAL / LAB data · UNKNOWN · UNVERIFIED: not yet confirmed against a primary source

About the evidence: the only published human data are four weeks long, in a small phase 1 trial run by the developer. A review places it among next-generation co-agonists. ^R7

What is it?

Related pages: tirzepatide, retatrutide, semaglutide, ct-996.

Does it work?

Human Phase 1: 4.7–8.0% weight loss at day 29 vs 0.5% on placebo; better fasting and glucose-tolerance values. ^R1
Unknown Phase 2 (n = 469): completed, results not peer-reviewed. ^R2

Is it safe?

Human Phase 1: mostly mild to moderate adverse events, consistent with other incretin drugs. ^R1
Unknown No long-term data.

Pipeline status (investigational)

Sponsor: Roche (via Carmot Therapeutics). ^R8
Trials: NCT06525935 phase 2, completed Dec 2025 ^R2; NCT07351045 phase 3 obesity, primary completion estimated Jul 2028 ^R8; NCT07889648 phase 3 vs tirzepatide in type 2 diabetes, estimated Apr 2029. ^R9
Expected readouts: phase 2 publication pending UNVERIFIED timing; phase 3 not before 2028.

Gray-market vials: extra risks

A gray-market vial has no quality control and no guarantee of identity, strength or sterility. We test retail vials blind under the Open Peptide Standard; see /tests/. A passing test covers one batch on one date and does not mean the compound is safe.

Is it legal?

US: not FDA-approved; no Drugs@FDA application found (openFDA searched Oct 27, 2026).
Compounding: not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page. ^{R3, R4, R5}
Sport: not named on WADA's 2026 list; as a drug not approved anywhere for human use it falls under S0 (non-approved substances) ^R6.

Study details

These are amounts researchers used, not recommendations.

Study	People / model	Route	Amount used	Follow-up	Reported	Citation
Phase 1 (Chakravarthy 2026)	Adults with overweight/obesity	SC	Single doses 0.5–7.5 mg; 4 weekly doses 5–12 mg	29 days	−4.7% to −8.0% weight vs −0.5%	PMID 41319798

Full reference list (PubMed, CT.gov, FDA and WADA checked Oct 27, 2026)

^R1 Chakravarthy MV, et al. Mol Metab. 2026. PMID 41319798
^R2 ClinicalTrials.gov NCT06525935, phase 2, obesity, Carmot, completed (CT.gov API v2, checked Oct 27, 2026). https://clinicaltrials.gov/study/NCT06525935
^R3 FDA, 503A bulk drug substances categories list (updated May 14, 2026). https://www.fda.gov/media/94155/download
^R4 FDA, 503B bulk drug substances categories list (updated Mar 21, 2025). https://www.fda.gov/media/94164/download
^R5 FDA, Certain bulk drug substances for use in compounding that may present significant safety risks (content current Apr 22, 2026). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
^R6 WADA. The 2026 Prohibited List, S0 Non-approved substances. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
^R7 Neumann J, et al. Naunyn Schmiedebergs Arch Pharmacol. 2026. PMID 42768195
^R8 ClinicalTrials.gov NCT07351045, phase 3, obesity without diabetes, Roche, recruiting (CT.gov API v2, checked Oct 27, 2026). https://clinicaltrials.gov/study/NCT07351045
^R9 ClinicalTrials.gov NCT07889648, phase 3 vs tirzepatide in type 2 diabetes, Roche, not yet recruiting (CT.gov API v2, checked Oct 27, 2026). https://clinicaltrials.gov/study/NCT07889648

Disclaimer

This page is for education and harm reduction, not medical advice or a recommendation to use CT-388 (enicepatide, RO7795068). This is an investigational drug. It is available only inside registered clinical trials; products sold online under this name are unregulated. Report problems to FDA MedWatch (https://www.fda.gov/safety/medwatch).